PDGFRA non-D842V exon 18 mutations in GIST are imatinib-SENSITIVE (distinct from D842V)....
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PDGFRA-EXON18-NON-D842-GIST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GIST |
| Sources | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-PDGFRA |
|---|---|
| Variant | exon 18 non-D842V mutation (e.g., D846Y, N848K, Y849K, deletion DIM842-844) |
| Disease | DIS-GIST |
| ESCAT tier | IB |
| Recommended combinations | imatinib 400 mg/day (1L advanced/metastatic non-D842V exon 18 PDGFRA), avapritinib (alternative; investigational) |
| Evidence summary | PDGFRA non-D842V exon 18 mutations in GIST are imatinib-SENSITIVE (distinct from D842V). Imatinib 400 mg/day is standard 1L — responses comparable to KIT exon 11 GIST. Avapritinib also active. Genotyping is mandatory to distinguish D842V (avapritinib) from non-D842V exon 18 (imatinib-first). |
Notes
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST. Adjuvant imatinib applies in high-risk resected non-D842V PDGFRA GIST (3 yr).
Used By
No reverse references found in the YAML corpus.